Johnson & Johnson – J&J has completed the acquisition of Halda Therapeutics which is a clinical-stage biotechnology firm for an amount of $3.05bn in cash.
This move goes on to bring the Regulated Induced Proximity Targeting Chimera -RIPTAC platform from Halda to oncology portfolio of J&J, supporting the development when it comes to oral, targeted therapies for many solid tumours, such as that of prostate cancer.
The acquisition goes on to include HLD-0915, which is a clinical-stage, once-daily oral therapy as far as prostate cancer is concerned. This therapy makes use of the RIPTAC platform for accurate targeting when it comes to cancer cells, hence aiming to address the resistance mechanisms.
Moreover, the deal also adds early-stage candidates in terms of breast, lung as well as other tumour types, by way of using RIPTAC technology, to the portfolio of J&J.
The company went on to indicate that this platform could potentially help with the development of more targeted therapies that go beyond oncology.
With the deal getting closed in 2025, J&J looks for earnings dilution within the fourth quarter of 2025 and into 2026.
The overall impact on the adjusted earnings per share is anticipated to be almost $0.20, which have been divided equally between 2025 and 2026, thereby reflecting the charges that are related to employee equity of Halda, financing, as well as integration costs.
Jennifer Taubert, the J&J innovative medicine worldwide chairman as well as the executive vice president said that this strategic landmark highlights their commitment to go ahead and redefine cancer treatment with breakthrough science as well as transformative medicines.
He added that they are indeed excited to formally welcome talented Halda team to J&J and they indeed look forward to working together so as to achieve their shared objectives of eradicating cancer.
According to John Reed, the J&J innovative medicine R&D executive vice-president they have finalised this acquisition, and will focus on advancing the potential of such promising pipeline of novel product candidates and also harnessing the powerful RIPTAC platform in order to discover more molecules within oncology and even beyond.
It was in November 2025, that J&J signed a definitive agreement for acquisition of this clinical-stage biotechnology firm.
